MeganElizabeth VereshCaramMDMSc

Oncology • Ann Arbor, MI

Genitourinary Oncology

Physician

Join to view full profile

Dr. Caram is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Caram's full profile

Already have an account?

Office
1500 E Medical Center Dr
B1 Floor Cancer Recp D
Ann Arbor, MI 48109
Phone+1 734-647-8903

Fax+1 734-232-9357
Is this information wrong?

Summary

Dr. Megan Caram is an oncologist in Ann Arbor, MI and is affiliated with multiple hospitals in the area, including Veterans Affairs Ann Arbor Healthcare System and Michigan Medicine. She received her medical degree from New York Medical College and has been in practice 10 years. She specializes in genitourinary oncology clinically and conducts health services research focused on understanding the factors that lead to variation in the care of patients with advanced prostate cancer.

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Michigan Health SystemResidency, Internal Medicine, 2007 - 2010
New York Medical CollegeClass of 2007

Certifications & Licensure

MI State Medical License 2007 - 2024
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
Stephanie Daignault-Newton, , Daniel Triner, Udit Singhal, Michael Sessine, Robert T Dess, Megan E V Caram, Tudor Borza, Kevin B Ginsburg, Brian R Lane, Todd M Morgan> ;Urologic Oncology. 2024 Apr 2
Value-based payment models and management of newly diagnosed prostate cancer.
Kaufman, S., Oerline, M., Maganty, A., Faraj, K., Caram, M., Shahinian, V., Hollenbeck, B.> ;Cancer Medicine. 2023 Dec 26
Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.
Kumbier, K., Burns, J., Sparks, J., Skolarus, T., Nguyen, C., Kobe, C., Bauman, J., Tsao, P., Caram, M.> ;JCO Oncology Practice. 2024 Jan 1
Acquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System.
Kassem S Faraj, Samuel R Kaufman, Lindsey A Herrel, Avinash Maganty, Mary Oerline, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck> ;Urology Practice. 2023 Nov 1
Association Between Urologist Merit-Based Incentive Payment System Performance and Quality of Prostate Cancer Care.
Avinash Maganty, Samuel R Kaufman, Mary K Oerline, Kassem Faraj, Megan E V Caram, Brent K Hollenbeck, Vahakn B Shahinian> ;Urology Practice. 2024 Jan 1
In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.
Dawson Hill, Samuel R Kaufman, Mary K Oerline, Kassem Faraj, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck, Avinash Maganty> ;JNCI Cancer Spectrum. 2023 Jul 3
EDITORIAL COMMENT.
Kassem S Faraj, Megan E V Caram> ;Urology. 2023 Sep 1
Health care delivery system contributions to management of newly diagnosed prostate cancer.
Noah Krampe, Samuel R Kaufman, Mary K Oerline, Dawson Hill, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck, Avinash Maganty> ;Cancer Medicine. 2023 Aug 1
2 citations
A Positive Distress Screen…Now What? An Updated Call for Integrated Psychosocial Care.
Phoebe A Tsao, Jesse R Fann, Andrea L Nevedal, Lindsey E Bloor, Sarah L Krein, Megan E V Caram> ;Journal of Clinical Oncology. 2023 Nov 1
The perfect storm.
Megan E V Caram> ;Urologic Oncology. 2023 Sep 1
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide.
Phoebe A Tsao, Jennifer Burns, Kyle Kumbier, Jordan B Sparks, Shami Entenman, Lindsey E Bloor, Amy S B Bohnert, Ted A Skolarus, Megan E V Caram> ;Cancer Medicine. 2023 Aug 1
Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
Megan E V Caram, Kyle Kumbier, Jennifer Burns, Jordan B Sparks, Phoebe A Tsao, Kristian D Stensland, Samuel L Washington 3rd, Brent K Hollenbeck, Vahakn Shahinian, Ted...> ;Cancer Medicine. 2023 Mar 1
2 citations
Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.
Nnenaya Agochukwu-Mmonu, Yongmei Qin, Samuel Kaufman, Mary Oerline, Randy Vince, Danil Makarov, Megan V Caram, Christina Chapman, Joseph Ravenell, Brent K Hollenbeck, ...> ;JCO Oncology Practice. 2023 May 1
1 citations
A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.
Irene Tsung, Edward Green, Phillip Palmbos, Zachery Sloan, Zachery R Reichert, Ulka Vaishampayan, David C Smith, Megan E V Caram, Sarah Yentz, Stephanie Daignault-Newt...> ;The Journal of Urology. 2023 Jan 1
Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy.
Kristian D Stensland, Theresa Devasia, Megan E V Caram, Christina Chapman, Alexander Zaslavsky, Todd M Morgan, Brent K Hollenbeck, Jordan B Sparks, Jennifer Burns, Var...> ;JNCI Cancer Spectrum. 2022 May 2
7 citations
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Lillian Y Lai, Mary K Oerline, Megan E V Caram, Phoebe A Tsao, Samuel R Kaufman, Brent K Hollenbeck, Vahakn B Shahinian> ;Journal of the National Cancer Institute. 2022 Aug 8
1 citations
Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy.
Phoebe A Tsao, Ryan D Ross, Amy S B Bohnert, Bhramar Mukherjee, Megan E V Caram> ;The Oncologist. 2022 Apr 5
2 citations
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
Lillian Y Lai, Samuel R Kaufman, Mary K Oerline, Megan E V Caram, Avinash Maganty, Brent K Hollenbeck, Vahakn B Shahinian> ;JNCI Cancer Spectrum. 2022 Mar 2
AUTHOR REPLY.
Lillian Y Lai, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck> ;Urology. 2022 Mar 1
2 citations
PD05-06 PROMOTIONAL PAYMENTS TO MEDICAL ONCOLOGISTS AND UROLOGISTS AND PRESCRIPTIONS FOR ABIRATERONE AND ENZALUTAMIDE
Lillian Y. Lai, Mary K. Oerline, Samuel R. Kaufman, Lindsey A. Herrel, Ted A. Skolarus, Stacie B. Dusetzina, Chad Ellimoottil, Vahakn B. Shahinian, Brent K. Hollenbeck...> ;Urology. 2021 Nov 30
6 citations
Learning from the "tail end" of de-implementation: the case of chemical castration for localized prostate cancer.
Ted A. Skolarus, Jane Forman, Jordan B. Sparks, Tabitha Metreger, Sarah T. Hawley, Megan E.V. Caram, Lesly A. Dossett, Alan Paniagua-Cruz, Danil V. Makarov, John T. Le...> ;Implementation Science Communications. 2021 Oct 28
6 citations
Has declining opioid dispensing to cancer patients been tailored to risk of opioid harms
Tarlise Townsend, Talya Salz, Rebecca L. Haffajee, Megan E.V. Caram, Fumiko Chino, Amy S.B. Bohnert> ;Journal of Pain and Symptom Management. 2021 Oct 14
7 citations
Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
Angelina Y Jeong, Eric B Schwartz, Andrea Roman, Rachel L McDevitt, Mary K. Oerline, Elyssa Henry, Christine M. Veenstra, Megan E.V. Caram> ;JCO Oncology Practice. 2021 Sep 7
EDITORIAL COMMENT.
Phoebe A Tsao, Megan E V Caram> ;Urology. 2021 Jul 1
4 citations
Veridical causal inference using propensity score methods for comparative effectiveness research with medical claims
Ryan D. Ross, Xu Shi, Megan E.V. Caram, Phoebe A. Tsao, Paul Lin, Amy S.B. Bohnert, Min Zhang, Bhramar Mukherjee> ;Health Services & Outcomes Research Methodology. 2021 Jun 1
Join now to see all